Health and Wellness

STAT+: As investor for AHA, ‘Venture Valkyrie’ argues ‘good medicine is good business’

Lisa Suennen: “We’re just steaming ahead with our eyes wide open.”American Heart Association Ventures Elizabeth Cooney is a reporter at STAT, specializing in cardiovascular disease, covering critical issues related to

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.

Lasted Health and Wellness

Trying To Lose Weight In 2025? Don’t Skip Breakfast

Eating a balanced breakfast has been linked to better weight loss and health markers by scientists probing the diets of

Ozempic’s logistical challenges have doctors look to team approach

Life was looking up for Carlos Campos, a 72-year-old retired machinist living in Tukwila, Wash., with his wife and daughter.

Active lifestyle significantly lowers risk of 19 chronic diseases, study finds

Physical activity has long been known to have numerous health benefits, and a new study conducted at the University of

Could Trump Make A Big Weight Loss Drug Deal?

So, Trump’s choice is a difficult one. Does he stick with his party’s long-standing opposition to government price controls on

Smoking just one cigarette can reduce lifespan by about 20 minutes

A recent study conducted by behavioral scientists at University College London has revealed shocking information about the impact of smoking

The PBM Bill Failed. Americans Dodged A Bullet.

The pharmaceutical industry middlemen known as Pharmacy Benefit Managers (PBMs) have long been under scrutiny for their opaque practices when

Health officials assess the threat of H5N1

The threat of Highly pathogenic H5N1 avian influenza A virus (HPAI H5N1) remains a concern, but public health experts in

GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet

This trend of non-persistence with weight loss drugs adds another layer of complexity to the cost-effectiveness of GLP-1 agonists. Even